Edwards Lifesciences price target raised to $95 from $85 at Mizuho

Mizuho analyst Anthony Petrone raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $85 and keeps a Buy rating on the shares. Mizuho’s Q1 U.S. transcatheter aortic valve replacement data shows Edwards’ underlying TAVR volumes improved to 14% versus 10% exiting Q4 and that the company lost 300-400 basis points of share to Medtronic (MDT), the analyst tells investors in a research note. The firm raised its Q1 U.S. TAVR revenue growth target 10.5% from 9%, which supports the higher price target.